PTC Therapeutics, Inc. (PTCT)
$59.92-4.77%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5.0B
- Beta
- 0.55
- P/E (TTM)
- -122.29
- Short % float
- 12.53%
- Days to cover
- 6.1
- SI change
- -5.9%
- 1W
- -5.93%
- 1M
- -9.87%
- vs SPY 1W
- -5.80%
- vs SPY 1M
- -12.37%
Industry peers
FMP comparable companies · ranked by market cap
- BBIOSELLBridgeBio Pharma, Inc.$12.8BRECOVERYQ 18$65.35-3.73%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80-1.82%
- KRYSSELLKrystal Biotech, Inc.$9.8BBEARQ 46$331.61-3.29%
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28-2.95%
- DYNSELLDyne Therapeutics, Inc.$3.1BCRISISQ 3$16.64-4.14%
- SRPTSELLSarepta Therapeutics, Inc.$1.9BCRISISQ 13$17.85-5.33%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$15.48-2.48%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-4.27%
- SLDBSELLSolid Biosciences Inc.$676MCRISISQ -13$6.87-13.26%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PTCT?
- LOPJLB’s latest quantitative signal on PTC Therapeutics, Inc. (PTCT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PTCT in?
- PTC Therapeutics, Inc. (PTCT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does PTC Therapeutics, Inc. (PTCT) do?
- PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of developmentâfrom early research and preclinical studies to clini…